Who is sponsoring NCT05870657?

NCT05870657 is sponsored by Novartis Pharmaceuticals.

What condition does NCT05870657 study?

NCT05870657 studies High Levels of Low-density Lipoprotein Cholesterol.

Is NCT05870657 still recruiting?

NCT05870657 is currently completed. Last updated 23 May 2023.

Last reviewed 2023-05-23 · How we verify

NCT05870657

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adherence and Persistence to Inclisiran Among Early Users in Germany

Completed Last updated 23 May 2023

What this trial tests

trial in High Levels of Low-density Lipoprotein Cholesterol in 1,109 participants. Completed in 12 May 2022.

Timeline

16 February 2022

Primary endpoint
12 May 2022

12 May 2022

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,109
Start date	16 February 2022
Primary completion	12 May 2022
Estimated completion	12 May 2022
Sites	1 location across Switzerland

Conditions studied

High Levels of Low-density Lipoprotein Cholesterol — all drugs for High Levels of Low-density Lipoprotein Cholesterol →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with High Levels of Low-density Lipoprotein Cholesterol. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present study was a descriptive, non-interventional, retrospective cohort study aimed at evaluating early data on adherence, persistence, and treatment patterns among patients receiving inclisiran and other lipid-lowering therapies (LLT) in a real-world setting in Germany. Analysis was carried out using the IQVIA™ LRx database.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Current RNA strategies in treating cardiovascular diseases.
Chia SPS, Pang JKS, Soh BS. · · 2024 · cited 13× · PMID 38291757 · DOI 10.1016/j.ymthe.2024.01.028

Verify or expand the search:

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05870657 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 23 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05870657.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing